⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0043

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2022-04-18
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-04 (study day 96); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 152); relationship: N

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-14 (study day 349); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-12 (study day 377); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-24 (study day 450); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 485); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-07-05 (study day 797); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.